$DCGO

DocGo Inc. (DCGO): Results of Operations and Financial Condition

DocGo Inc. (DCGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 DocGo Announces Second Quarter 2026 Results Company Signs Definitive Agreement to Acquire Virtual Care Provider Hicuity Health, Perceptive Advisors Commits to New Term Loan Funding Management to Host Conference Call and Webcast Today at 5:00 PM Eastern Time NEW YORK,

Original reporting
Published Aug 17, 2026, 8:24 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 17, 2026, 8:28 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$DCGO
Neutral
medium confidence
Mentioned
$DCGO
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$DCGONeutralMed
01

Why it matters

This is an event-driven catalyst. The market will likely reprice based on merger economics, expected timing to closing, and deal-risk factors (approvals, consents, and potential adjustments).

02

Market read

A merger plan filing is a direct catalyst for DCGO, increasing deal-volatility and shifting attention to transaction terms and closing path.

03

What to watch

Traders should focus on closing conditions, regulatory approvals, termination rights, and any earnout or post-closing adjustment payment structure, none of which are included in the scraped excerpt.

Relevance 7/10Novelty 5/10Timing: filed Aug. 17, 2026 after market close (8-K filing)

Background

DocGo Inc. (DCGO) filed an SEC Form 8-K on Aug. 17, 2026, citing entry into a material definitive agreement and providing merger-related exhibit text.

Company-level read

Ticker impact

$DCGONeutralMedium confidence
Context

DocGo filed an 8-K with an agreement and plan of merger, indicating a material definitive transaction affecting DocGo’s equity and deal risk.

Expected impact

Near-term price action likely driven by deal-speculation and risk of closing/terms, with volatility elevated until clearer economics and regulatory/consent milestones emerge.

Evidence & confidence

The text confirms a material definitive agreement and merger plan were filed, but it does not include the key economic terms (consideration, earnout mechanics, closing conditions) needed to forecast direction or magnitude.

Market effects

Could modestly affect sentiment around healthcare services/MaaS providers if the deal reflects consolidation or strategic repositioning, but no sector-wide datapoints are provided here.

No regional macro or cross-border market details disclosed in the provided text.

No global market or international regulatory details disclosed in the provided text.

Counterpoint

A merger agreement filing can be largely procedural if key terms are already known; without disclosed economics here, the incremental trading edge may be limited.

Key entities

  • DocGo Inc.

    Subject issuer filing the 8-K and entering a material definitive agreement tied to a merger plan.

  • Ambulnz Holdings, LLC

    Named party in the merger agreement as a counterparty to the transaction structure.

  • Hicuity Health, Inc.

    Named party in the merger agreement, indicating it is part of the transaction structure.

  • HH Merger Sub, LLC

    Merger sub entity referenced in the agreement and plan of merger.

  • Concord Innovation Fund II, LP

    Named as a party in the merger agreement, including as shareholder representative in the excerpt.

Related articles

Med

DocGo Inc. Q2 2026 Earnings Call Summary

DocGo Inc. reported Q2 2026 earnings, highlighting a 19% year-over-year revenue increase in core business lines, despite a $6.3M adjusted EBITDA loss. The company announced its largest acquisition, Hicuity Health, aiming to integrate hospital and home care. Management expects to achieve positive adjusted EBITDA by year-end 2026, with revenue guidance narrowed to $305M-$310M. Cost synergies and efficiency programs are expected to drive future growth.

$DCGOMed

DocGo Shares Tumble After Earnings Miss and Wider Loss Forecast

DocGo (DCGO) shares fell 12.7% pre-market Tuesday after Q2 2026 earnings missed estimates, with a $0.16 loss per share vs. expected $0.10. Revenue was $73.4M, down 8.7% YoY, and the company widened its full-year adjusted EBITDA loss forecast to $17M-$22M. The decline followed the end of migrant-related contracts, though core revenue grew 19%. The stock trades near its 52-week low of $0.451.

$DCGOMed

DocGo Q2 Earnings Call Highlights

DocGo reported record service volumes in Q2, with year-over-year growth across all core businesses. The company acquired Hicuity, assuming $52M in debt and issuing 2% equity. DocGo's revenue rose to $52M in medical transportation but fell in mobile health due to migrant-related work decline. Adjusted EBITDA loss narrowed to $6.3M. The company updated its full-year outlook, expecting a wider EBITDA loss of $17M-$22M. DocGo has $48.1M in cash and expects positive adjusted EBITDA run rate by year-e

$DCGOMed

DocGo Inc (DCGO) (Q2 2026) Earnings Call Highlights: Record Volumes and Strategic

DocGo Inc (DCGO) reported Q2 2026 revenue of $73.4M, down from $80.4M YoY, and widened its adjusted EBITDA loss guidance to $17M-$22M. Gross margins declined due to lower margins in the Mobile Health segment and higher fuel costs. The company's cash position decreased to $48.1M. The Hicuity acquisition faces regulatory and customer approval hurdles. Organic revenue grew approximately 5% YoY. The company aims to achieve adjusted EBITDA breakeven by the end of 2026 through revenue growth, improved

$DCGOHighAI 9/10

Why is DocGo stock tumbling today?

DocGo (DCGO) shares fell 12.7% pre-open to $0.62 after its Q2 2026 adjusted loss was $0.16 per share versus $0.10 consensus. Revenue was $73.4M, below $75.4M forecast and down 8.7% YoY, tied to wind-down of migrant contracts. It widened FY2026 adjusted EBITDA loss to $17M-$22M and agreed to acquire Hicuity Health (~$65M trailing revenue).